explore -WSS

explore

author：entertainment 2025-09-30 21:07:41 - browse：82292

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： See how much Covid

explore

WSS

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Ionis drug prevents swelling attacks due to hereditary angioedema

ASCO: Palliative care found as helpful given virtually as in person

Ultragenyx gene therapy for rare liver ailment succeeds in late

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

hotspot

explore

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Analysis of telehealth claims data suggest service duplication

As demand for Covid shots wanes, Moderna seeks its next success

A virus, fished out of a lake, may have saved a man’s life

Apple is now the first public company to be valued at $3 trillion

Bill would stop addiction treatment from triggering child abuse inquiry

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

HIV drugs protect against transmission, even in unprotected sex

focus

Intellia reports positive results for its CRISPR

Chemotherapy drug shortage eases slightly but still widespread

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Was Amgen transparent enough on FDA's concern on cancer drug?

Why age limits for politicians are a terrible idea

FDA's Pazdur wants cancer trials to range beyond China alone

knowledge

hotspot

explore

focus